Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ptc Therapeutics (PTCT) Current Deferred Revenue: 2012-2024

Historic Current Deferred Revenue for Ptc Therapeutics (PTCT) over the last 11 years, with Dec 2024 value amounting to $5.5 million.

  • Ptc Therapeutics' Current Deferred Revenue was N/A to $1.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.7 million, marking a year-over-year change of. This contributed to the annual value of $5.5 million for FY2024, which is 587.27% up from last year.
  • Ptc Therapeutics' Current Deferred Revenue amounted to $5.5 million in FY2024, which was up 587.27% from $801,000 recorded in FY2023.
  • Ptc Therapeutics' Current Deferred Revenue's 5-year high stood at $5.5 million during FY2024, with a 5-year trough of $801,000 in FY2023.
  • Moreover, its 3-year median value for Current Deferred Revenue was $1.4 million (2022), whereas its average is $2.6 million.
  • Per our database at Business Quant, Ptc Therapeutics' Current Deferred Revenue plummeted by 64.10% in 2020 and then spiked by 587.27% in 2024.
  • Ptc Therapeutics' Current Deferred Revenue (Yearly) stood at $4.2 million in 2020, then reached $1.4 million in 2022, then plummeted by 40.71% to $801,000 in 2023, then soared by 587.27% to $5.5 million in 2024.